> top > docs > PMC:7228307 > spans > 47488-49159 > annotations

PMC:7228307 / 47488-49159 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
914 359-367 Gene denotes FcγRIIIa Gene:2214
915 403-411 Gene denotes FcγRIIIa Gene:2214
916 449-456 Gene denotes FcγRIII Gene:14131
917 529-534 Species denotes mouse Tax:10090
918 240-268 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 502-525 Disease denotes reduced lymphoma growth MESH:D006130
920 314-319 Mutation denotes S329D p.S329D
921 324-329 Mutation denotes I332E p.I332E
941 624-628 Gene denotes HER2 Gene:2064
942 662-666 Gene denotes HER2 Gene:2064
943 783-791 Gene denotes FcγRIIIa Gene:2214
944 869-876 Gene denotes FcγRIIb Gene:2213
945 1030-1034 Gene denotes HER2 Gene:13866
946 1101-1105 Gene denotes HER2 Gene:13866
947 911-915 Gene denotes FcγR Gene:2213
948 1132-1136 Species denotes mice Tax:10090
949 543-555 Chemical denotes Margetuximab MESH:C000617981
950 633-644 Chemical denotes trastuzumab MESH:D000068878
951 971-982 Chemical denotes trastuzumab MESH:D000068878
952 988-1000 Chemical denotes margetuximab MESH:C000617981
953 678-685 Disease denotes cancers MESH:D009369
954 1117-1122 Disease denotes tumor MESH:D009369
955 725-730 Mutation denotes L235V p.L235V
956 732-737 Mutation denotes F243L p.F243L
957 739-744 Mutation denotes R292P p.R292P
958 746-751 Mutation denotes Y300L p.Y300L
959 756-761 Mutation denotes P396L p.P396L
967 1445-1453 Gene denotes FcγRIIIa Gene:2214
968 1152-1164 Chemical denotes ocaratuzumab MESH:C550337
969 1256-1263 Disease denotes cancers MESH:D009369
970 1275-1295 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 1300-1328 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 1350-1355 Mutation denotes P247I p.P247I
973 1360-1365 Mutation denotes A339Q p.A339Q
976 1572-1580 Gene denotes FcγRIIIa Gene:2214
977 1552-1558 Chemical denotes glycan MESH:D011134

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T385 19-30 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 49-60 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T387 93-96 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T388 158-166 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T389 248-259 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T390 712-723 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T391 1036-1041 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T392 1308-1319 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T84 240-268 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T85 248-268 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T86 260-268 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T87 466-470 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T88 510-518 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T89 562-566 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T90 1017-1021 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T91 1117-1122 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T92 1275-1295 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0011508|http://purl.obolibrary.org/obo/MONDO_0018908
T94 1279-1295 Disease denotes Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0004952
T95 1287-1295 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T96 1300-1328 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T97 1308-1328 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T98 1320-1328 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T99 1483-1487 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T816 16-18 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T817 80-82 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T818 126-136 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T819 137-139 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T820 140-142 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T821 153-157 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T822 310-312 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T823 359-361 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T824 403-405 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T825 449-451 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T826 529-534 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T827 581-583 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T828 783-785 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T829 869-871 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T830 904-905 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T831 911-913 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T832 1036-1050 http://purl.obolibrary.org/obo/CL_0001034 denotes cells in vitro
T833 1171-1173 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T834 1245-1246 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T835 1329-1331 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T836 1336-1338 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T837 1445-1447 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T838 1539-1541 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T839 1572-1574 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T840 1592-1593 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T240 19-30 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T241 19-24 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T242 25-30 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T243 49-60 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T244 49-54 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T245 55-60 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T246 712-723 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T247 712-717 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T248 718-723 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T223 519-525 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T224 1036-1041 http://purl.obolibrary.org/obo/CL_0000000 denotes cells

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T51 19-30 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T52 49-60 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T53 712-723 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
914 359-367 Gene denotes FcγRIIIa Gene:2214
915 403-411 Gene denotes FcγRIIIa Gene:2214
916 449-456 Gene denotes FcγRIII Gene:14131
917 529-534 Species denotes mouse Tax:10090
918 240-268 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 502-525 Disease denotes reduced lymphoma growth MESH:D006130
920 314-319 Mutation denotes S329D p.S329D
921 324-329 Mutation denotes I332E p.I332E
941 624-628 Gene denotes HER2 Gene:2064
942 662-666 Gene denotes HER2 Gene:2064
943 783-791 Gene denotes FcγRIIIa Gene:2214
944 869-876 Gene denotes FcγRIIb Gene:2213
945 1030-1034 Gene denotes HER2 Gene:13866
946 1101-1105 Gene denotes HER2 Gene:13866
947 911-915 Gene denotes FcγR Gene:2213
948 1132-1136 Species denotes mice Tax:10090
949 543-555 Chemical denotes Margetuximab MESH:C000617981
950 633-644 Chemical denotes trastuzumab MESH:D000068878
951 971-982 Chemical denotes trastuzumab MESH:D000068878
952 988-1000 Chemical denotes margetuximab MESH:C000617981
953 678-685 Disease denotes cancers MESH:D009369
954 1117-1122 Disease denotes tumor MESH:D009369
955 725-730 Mutation denotes L235V p.L235V
956 732-737 Mutation denotes F243L p.F243L
957 739-744 Mutation denotes R292P p.R292P
958 746-751 Mutation denotes Y300L p.Y300L
959 756-761 Mutation denotes P396L p.P396L
967 1445-1453 Gene denotes FcγRIIIa Gene:2214
968 1152-1164 Chemical denotes ocaratuzumab MESH:C550337
969 1256-1263 Disease denotes cancers MESH:D009369
970 1275-1295 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 1300-1328 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 1350-1355 Mutation denotes P247I p.P247I
973 1360-1365 Mutation denotes A339Q p.A339Q
976 1572-1580 Gene denotes FcγRIIIa Gene:2214
977 1552-1558 Chemical denotes glycan MESH:D011134

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T44 529-534 Species denotes mouse NCBItxid:10090|NCBItxid:10088
T46 1132-1136 Species denotes mice NCBItxid:10095|NCBItxid:10088

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T274 0-30 Sentence denotes Mutation of the Fc amino acids
T275 31-143 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 144-424 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 425-542 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 543-922 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 923-1137 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 1138-1509 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 1510-1671 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T596 153-157 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T605 1147-1151 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T384 19-30 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T385 49-60 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 93-96 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T387 158-166 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T388 248-259 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T389 712-723 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T390 1036-1041 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T391 1308-1319 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T110 466-470 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 475-487 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 519-525 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 562-566 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 1017-1021 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 1483-1487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T37 240-268 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T38 510-518 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T39 1117-1122 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T40 1275-1295 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0018908
T41 1300-1328 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T33 240-268 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 510-518 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 1117-1122 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 1275-1295 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 1300-1328 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T110 466-470 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 475-487 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 519-525 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 562-566 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 1017-1021 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 1483-1487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T110 466-470 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 475-487 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 519-525 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 562-566 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 1017-1021 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 1483-1487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T274 0-30 Sentence denotes Mutation of the Fc amino acids
T275 31-143 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 144-424 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 425-542 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 543-922 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 923-1137 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 1138-1509 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 1510-1671 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T33 240-268 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 510-518 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 1117-1122 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 1275-1295 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 1300-1328 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550